Tom Croce
Vice President, Global Patient Advocacy Jazz Pharmaceuticals plc
Tom Croce is vice president for global patient advocacy and engagement at Jazz Pharmaceuticals, the fully integrated biopharmaceutical company with a diverse portfolio of approved and experimental medicines in neuroscience and oncology. Tom and his team are responsible for identification and integration of patient perspectives across the entire development and commercial continuum, while ensuring meaningful representation to patient, caregiver and advocate partners around the world. He is also responsible for building and implementing the company’s social impact strategy. Tom is a member of Jazz’ global leadership team as well as its legal and corporate affairs leadership team. Prior to joining Jazz, Tom was vice president for global patient advocacy at bluebird bio where he contributed to the development and approval of two gene therapies for severe genetic diseases. Tom also educated and activated the advocacy community on the transformative nature of regenerative medicine and furthered THE company’s diversity, equity and inclusion initiatives. Earlier, Tom served as vice president, global advocacy relations for Amgen and held related positions at other companies. A graduate of the Philadelphia College of Pharmacy, University of Sciences, Tom and his family live outside of Boston.
Seminars
Sustaining patient engagement measurement across multi-year programs is increasingly difficult as teams shrink, roles evolve, and priorities shift. This interactive workshop focuses on how to protect measurement continuity, credibility, and impact through organizational change – combining cross-functional systems thinking with practical strategies for adapting when resources are constrained. Participants will explore how to align stakeholders, leverage existing tools, and evolve their approach without losing momentum or trust.
This Workshop Will Gather Experts to Discuss:
- Designing cross-functional processes that sustain measurement across departments and long-term trials
- Leveraging existing technology and systems to capture engagement metrics efficiently
- Maintaining shared accountability across patient advocacy, clinical, medical, and commercial teams
- Prioritizing meaningful, defensible metrics that demonstrate impact on patient experience and trial outcomes
- Adapting measurement approaches during organizational change, budget pressure, or shifting priorities
